Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Depreciation & Amortization (CF) (2016 - 2025)

Sangamo Therapeutics has reported Depreciation & Amortization (CF) over the past 16 years, most recently at $959000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $959000.0 for Q4 2025, down 22.72% from a year ago — trailing twelve months through Dec 2025 was $4.0 million (down 22.44% YoY), and the annual figure for FY2025 was $4.0 million, down 22.44%.
  • Depreciation & Amortization (CF) for Q4 2025 was $959000.0 at Sangamo Therapeutics, down from $989000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for SGMO hit a ceiling of $5.5 million in Q3 2023 and a floor of $959000.0 in Q4 2025.
  • Median Depreciation & Amortization (CF) over the past 5 years was $2.1 million (2021), compared with a mean of $2.3 million.
  • Biggest five-year swings in Depreciation & Amortization (CF): soared 87.87% in 2021 and later tumbled 77.83% in 2024.
  • Sangamo Therapeutics' Depreciation & Amortization (CF) stood at $2.8 million in 2021, then increased by 20.66% to $3.3 million in 2022, then crashed by 45.22% to $1.8 million in 2023, then tumbled by 32.07% to $1.2 million in 2024, then decreased by 22.72% to $959000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $959000.0 (Q4 2025), $989000.0 (Q3 2025), and $993000.0 (Q2 2025) per Business Quant data.